Avacta announces second dose escalation in the Phase I clinical study of AVA6000 Pro-doxorubicin
Avacta Group PLC (AIM:AVCT) Second dose escalation in phase 1 trial of AVA6000
ValiRx PLC (AIM:VAL) Update on VAL201 sub-license agreement
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, is today providing an update on its proposed sub-license agreement with
Vela Technologies (AIM:VELA) Statement re. potential investment in TruSpine
The Board of Vela (AIM:VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, announces that, on Friday 10 June 2022, the Company became aware of a
Open Orphan PLC (AIM:ORPH) £7.2m RSV human challenge study contract
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces thathVIVO,
N4 Pharma PLC (AIM:N4P) Work Programme Update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce an update on its current work
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
New York, June 9, 2022 – Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery.
Tiziana Life Sciences Announces Positive Clinical Results
In the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) Following Three Months of Dosing with Intranasal Foralumab.
Open Orphan PLC (AIM:ORPH) Board appointment
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces the
Open Orphan PLC (AIM:ORPH) Final results
Record revenues and EBITDA-profitability accompanied by significant operational progress
Open Orphan PLC (AIM:ORPH) GBP14.7m influenza contract signed
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that
Omega Diagnostics Gp (AIM:ODX) Result of Open Offer
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health products, announces the results of its Open Offer.
